

Letermovir Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
1.21	28.09.2024	66867-00022	Date of first issue: 27.02.2015

Section 1: Identification

Product identifier : Letermovir Liquid Formulation

Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical
Restrictions on use : Not applicable

Manufacturer or supplier's details

Company : MSD
Address : 50 Tuas West Drive
Singapore - Singapore 638408
Telephone : +1-908-740-4000
Emergency telephone number : 65 6697 2111 (24/7/365)
E-mail address : EHSDATASTEWARD@msd.com

Section 2: Hazard identification**Classification of the substance or mixture**

Not a hazardous substance or mixture.

GHS Label elements, including precautionary statements

No hazard pictogram, no signal word, no hazard statement(s), no precautionary statement(s) required.

Other hazards which do not result in classification

None known.

Section 3: Composition/information on ingredients

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
Letermovir	917389-32-3	≥ 1 -< 3

Section 4: First-aid measures**Description of necessary first-aid measures**

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.

Letermovir Liquid Formulation

Version 1.21	Revision Date: 28.09.2024	SDS Number: 66867-00022	Date of last issue: 06.04.2024 Date of first issue: 27.02.2015
-----------------	------------------------------	----------------------------	---

When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air.
Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.
Remove contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse.

In case of eye contact : Flush eyes with water as a precaution.
Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting.
Get medical attention.
Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and delayed

Risks : None known.

Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Indication of any immediate medical attention and special treatment needed

Treatment : Treat symptomatically and supportively.

Section 5: Fire-fighting measures**Extinguishing media**

Suitable extinguishing media : Water spray
Alcohol-resistant foam
Carbon dioxide (CO₂)
Dry chemical

Unsuitable extinguishing media : None known.

Special hazards arising from the substance or mixture

Specific hazards during fire-fighting : Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides

Special protective actions for fire-fighters

Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do

Letermovir Liquid Formulation

Version 1.21	Revision Date: 28.09.2024	SDS Number: 66867-00022	Date of last issue: 06.04.2024 Date of first issue: 27.02.2015
-----------------	------------------------------	----------------------------	---

so.
Evacuate area.

Section 6: Accidental release measures**Personal precautions, protective equipment and emergency procedures**

Personal precautions : Use personal protective equipment.
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions

Environmental precautions : Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Prevent spreading over a wide area (e.g. by containment or oil barriers).
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up

Methods for cleaning up : Soak up with inert absorbent material.
For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container.
Clean up remaining materials from spill with suitable absorbent.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

Section 7: Handling and storage**Precautions for safe handling**

Technical measures : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation : Use only with adequate ventilation.

Advice on safe handling : Do not breathe mist or vapours.
Do not swallow.
Avoid contact with eyes.
Avoid prolonged or repeated contact with skin.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
Take care to prevent spills, waste and minimize release to the environment.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working

Letermovir Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
1.21	28.09.2024	66867-00022	Date of first issue: 27.02.2015

place.

When using do not eat, drink or smoke.

Wash contaminated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

Conditions for safe storage, including any incompatibilities

Conditions for safe storage : Keep in properly labelled containers.
Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:
Strong oxidizing agents

Section 8: Exposure controls/personal protection**Control parameters****Occupational Exposure Limits**

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Letermovir	917389-32-3	TWA	0.4 mg/m ³ (OEB 2)	Internal

Appropriate engineering control measures : Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections).
All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.
Laboratory operations do not require special containment.

Individual protection measures, such as personal protective equipment (PPE)

Eye/face protection : Wear safety glasses with side shields or goggles.
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin protection : Work uniform or laboratory coat.

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type : Particulates type

Hand protection

Material : Chemical-resistant gloves

Letermovir Liquid Formulation

Version 1.21	Revision Date: 28.09.2024	SDS Number: 66867-00022	Date of last issue: 06.04.2024 Date of first issue: 27.02.2015
-----------------	------------------------------	----------------------------	---

Section 9: Physical and chemical properties

Appearance	: liquid
Colour	: clear
Odour	: odourless
Odour Threshold	: No data available
pH	: 7.5
Melting point/freezing point	: No data available
Initial boiling point and boiling range	: No data available
Flash point	: No data available
Evaporation rate	: No data available
Flammability (solid, gas)	: Not applicable
Flammability (liquids)	: No data available
Upper explosion limit / Upper flammability limit	: No data available
Lower explosion limit / Lower flammability limit	: No data available
Vapour pressure	: No data available
Relative vapour density	: No data available
Relative density	: No data available
Density	: No data available
Solubility(ies) Water solubility	: No data available
Partition coefficient: n-octanol/water	: Not applicable
Auto-ignition temperature	: No data available
Decomposition temperature	: No data available
Viscosity Viscosity, kinematic	: No data available
Explosive properties	: Not explosive

Letermovir Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
1.21	28.09.2024	66867-00022	Date of first issue: 27.02.2015

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Particle characteristics
Particle size : Not applicable

Section 10: Stability and reactivity

Reactivity : Not classified as a reactivity hazard.
Chemical stability : Stable under normal conditions.
Possibility of hazardous reactions : Can react with strong oxidizing agents.
Conditions to avoid : None known.
Incompatible materials : Oxidizing agents
Hazardous decomposition products : No hazardous decomposition products are known.

Section 11: Toxicological information

Information on likely routes of exposure : Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity

Not classified based on available information.

Components:**Letermovir:**

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg
LD50 (Mouse): > 2,000 mg/kg

Skin corrosion/irritation

Not classified based on available information.

Components:**Letermovir:**

Remarks : No data available

Serious eye damage/eye irritation

Not classified based on available information.

Components:**Letermovir:**

Remarks : No data available

Letermovir Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
1.21	28.09.2024	66867-00022	Date of first issue: 27.02.2015

Respiratory or skin sensitisation**Skin sensitisation**

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Components:**Letermovir:**

Remarks : No data available

Germ cell mutagenicity

Not classified based on available information.

Components:**Letermovir:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: Chromosome aberration test in vitro
Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
Species: Mouse
Application Route: Intraperitoneal injection
Result: negative

Germ cell mutagenicity - Assessment : Weight of evidence does not support classification as a germ cell mutagen.

Carcinogenicity

Not classified based on available information.

Reproductive toxicity

Not classified based on available information.

Components:**Letermovir:**

Effects on fertility : Test Type: Fertility/early embryonic development
Species: Rat, female
Application Route: Oral
Fertility: NOAEL: 240 mg/kg body weight
Result: No effects on fertility

Test Type: Fertility/early embryonic development
Species: Rat, male
Application Route: Oral
Fertility: LOAEL: 180 mg/kg body weight

Letermovir Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
1.21	28.09.2024	66867-00022	Date of first issue: 27.02.2015

Result: No effects on fertility
Remarks: The significance of these findings for humans is not certain.

Test Type: Fertility/early embryonic development
Species: Monkey, male
Application Route: Oral
Fertility: NOAEL: 240 mg/kg body weight
Result: No effects on fertility

Effects on foetal development : Test Type: Embryo-foetal development
Species: Rat
Developmental Toxicity: LOAEL: 250 mg/kg body weight
Result: Embryo-foetal toxicity
Remarks: Maternal toxicity observed.

Test Type: Embryo-foetal development
Species: Rabbit
Developmental Toxicity: LOAEL: 225 mg/kg body weight
Result: Embryo-foetal toxicity, Malformations were observed., Abortion
Remarks: Maternal toxicity observed.

Reproductive toxicity - Assessment : Some evidence of adverse effects on development, based on animal experiments.

STOT - single exposure

Not classified based on available information.

STOT - repeated exposure

Not classified based on available information.

Components:**Letermovir:**

Exposure routes : Ingestion
Target Organs : Liver, spleen, Blood
Assessment : May cause damage to organs through prolonged or repeated exposure.

Repeated dose toxicity**Components:****Letermovir:**

Species : Mouse
NOAEL : 40 mg/kg
LOAEL : 100 mg/kg
Application Route : Oral
Exposure time : 13 Weeks
Target Organs : Liver, spleen

Letermovir Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
1.21	28.09.2024	66867-00022	Date of first issue: 27.02.2015

Species : Rat
NOAEL : 150 mg/kg
Application Route : Oral
Exposure time : 26 Weeks
Remarks : No significant adverse effects were reported

Species : Monkey
NOAEL : 100 mg/kg
LOAEL : 200 - 250 mg/kg
Application Route : Oral
Exposure time : 39 Weeks
Target Organs : Kidney

Species : Rat
NOAEL : 60 mg/kg
LOAEL : 180 mg/kg
Exposure time : 13 Weeks
Target Organs : Testis, Blood, Liver, spleen, Immune system

Species : Monkey
NOAEL : 30 mg/kg
LOAEL : 100 mg/kg
Application Route : Oral
Exposure time : 4 Weeks
Target Organs : Blood

Aspiration toxicity

Not classified based on available information.

Experience with human exposure**Components:****Letermovir:**

Ingestion : Symptoms: Diarrhoea, Nausea, Vomiting, Headache, Dizziness, Fatigue, Back pain, Oedema, Rash, muscle pain

Section 12: Ecological information**Toxicity****Components:****Letermovir:**

Toxicity to fish : LC50 (Menidia beryllina (Silverside)): > 100 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 203

Toxicity to daphnia and other : EC50 (Americamysis): 16 mg/l
aquatic invertebrates Exposure time: 96 h

EC50 (Daphnia magna (Water flea)): > 100 mg/l

Letermovir Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue:
1.21	28.09.2024	66867-00022	06.04.2024
			Date of first issue: 27.02.2015

	Exposure time: 48 h Method: OECD Test Guideline 202
Toxicity to algae/aquatic plants	: EC50 (Pseudokirchneriella subcapitata (green algae)): > 8.8 mg/l Exposure time: 72 h Method: OECD Test Guideline 201 Remarks: No toxicity at the limit of solubility NOEC (Pseudokirchneriella subcapitata (green algae)): 8.8 mg/l Exposure time: 72 h Method: OECD Test Guideline 201 Remarks: No toxicity at the limit of solubility
Toxicity to fish (Chronic toxicity)	: NOEC (Pimephales promelas (fathead minnow)): 1 mg/l Exposure time: 32 d Method: OECD Test Guideline 210 Remarks: No toxicity at the limit of solubility
Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)	: NOEC (Daphnia magna (Water flea)): 1.2 mg/l Exposure time: 21 d Method: OECD Test Guideline 211
Toxicity to microorganisms	: EC50: > 972 mg/l Exposure time: 3 h Test Type: Respiration inhibition Method: OECD Test Guideline 209 NOEC: 29.6 mg/l Exposure time: 3 h Test Type: Respiration inhibition Method: OECD Test Guideline 209

Persistence and degradability**Components:****Letermovir:**

Biodegradability	: Result: rapidly degradable Biodegradation: 50 % Exposure time: 6.7 d
------------------	--

Bioaccumulative potential**Components:****Letermovir:**

Partition coefficient: n-octanol/water	: log Pow: 2.29
--	-----------------

Letermovir Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
1.21	28.09.2024	66867-00022	Date of first issue: 27.02.2015

Mobility in soil**Components:****Letermovir:**

Distribution among environmental compartments : log K_{oc}: 3.46

Other adverse effects

No data available

Section 13: Disposal considerations**Disposal methods**

Waste from residues	:	Do not dispose of waste into sewer. Dispose of in accordance with local regulations.
Contaminated packaging	:	Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

Section 14: Transport information**International Regulations****UNRTDG**

UN number	:	Not applicable
UN proper shipping name	:	Not applicable
Transport hazard class(es)	:	Not applicable
Subsidiary risk	:	Not applicable
Packing group	:	Not applicable
Labels	:	Not applicable
Environmentally hazardous	:	no

IATA-DGR

UN/ID No.	:	Not applicable
UN proper shipping name	:	Not applicable
Transport hazard class(es)	:	Not applicable
Subsidiary risk	:	Not applicable
Packing group	:	Not applicable
Labels	:	Not applicable
Packing instruction (cargo aircraft)	:	Not applicable
Packing instruction (passenger aircraft)	:	Not applicable

IMDG-Code

UN number	:	Not applicable
UN proper shipping name	:	Not applicable
Transport hazard class(es)	:	Not applicable
Subsidiary risk	:	Not applicable
Packing group	:	Not applicable
Labels	:	Not applicable
EmS Code	:	Not applicable

Letermovir Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
1.21	28.09.2024	66867-00022	Date of first issue: 27.02.2015

Marine pollutant : Not applicable

Transport in bulk according to IMO instruments

Not applicable for product as supplied.

Special precautions for user

Not applicable

Section 15: Regulatory information**Safety, health and environmental regulations specific for the product in question**

Workplace Safety and Health Act and Workplace Safety and Health (General Provisions) Regulations: This product is subjected to the SDS, labelling, PEL and other requirements in the Act/Regulations.

Environmental Protection and Management Act and : Not applicable
Environmental Protection and Management (Hazardous Substances) Regulations

Fire Safety (Petroleum and Flammable Materials) : Not applicable
Regulations

The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

Section 16: Other information

Revision Date : 28.09.2024

Further information

Sources of key data used to : Internal technical data, data from raw material SDSs, OECD
compile the Safety Data eChem Portal search results and European Chemicals Agen-
Sheet cy, <http://echa.europa.eu/>

Date format : dd.mm.yyyy

Full text of other abbreviations

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA

Letermovir Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
1.21	28.09.2024	66867-00022	Date of first issue: 27.02.2015

- International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

SG / EN